Avastin/Lucentis Update 44: United Kingdom Closer to Allowing Avastin for AMD

While the U.S. comes closer to showing the equivalency of Avastin to Lucentis for treating the wet form of age-related macular degeneration, when the CATT Study (Comparisons of Age-Related Macular Degeneration Treatments Trials) results become public, hopefully, some time this Spring, the UK’s health services are still fighting over whether or not they should study the two drugs to determine if Avastin would be appropriate for the Brits to use in their National Health Service.

Full Story →